, Volume 26, Issue 11, pp 937–949

A Cost-Effectiveness Analysis of Currently Approved Treatments for HBeAg-Positive Chronic Hepatitis B

Original Research Article


Background: A variety of pharmaceuticals are currently approved for the treatment of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB), but their relative economic value is unclear. The goal of this analysis was to compare the cost effectiveness of adefovir, entecavir, lamivudine, pegylated interferon and telbivudine.

Methods: We conducted a cost-utility analysis from a US payer perspective over a lifetime time horizon using a Markov model, in a hypothetical population with HBeAg-positive CHB and a mean age of 35 years. Disease progression probabilities, costs and quality-of-life data were derived from the literature. We assumed a treatment duration of 4 years, with the use of combination therapy for drug resistance. Nonresponders to pegylated interferon were assumed to receive entecavir in years 3–4. Sensitivity analyses, including probabilistic sensitivity analysis, were conducted to evaluate uncertainty in the results. All costs were valued in $US, year 2008 values. Costs and outcomes were discounted at 3% per anum.

Results: The 10-year cumulative incidence of cirrhosis for no treatment was 26.1%, and ranged from 19.7% to 23.8% with treatment; undiscounted life-years were 36.2 for no treatment, or ranged from 36.82 to 37.54 with treatment. Initiation with entecavir (18.70 QALYs) and pegylated interferon (18.64 QALYs) provided the largest treatment benefits overall, followed by telbivudine (18.55 QALYs). The probabilities of the interventions being cost effective at a threshold of $US50 000 per QALY were 57%, 37% and 2% for initiation with entecavir, pegylated interferon and telbivudine, respectively. The results were dependent on baseline seroconversion rate and the effect of viral suppression on cirrhosis risk.

Conclusions: Initiation of treatments for HBeAg-positive CHB with a favourable combination of seroconversion, viral suppression and resistance profile appear to offer the greatest clinical and economic value.

Supplementary material

40273_2012_26110937_MOESM1_ESM.pdf (119 kb)
Supplementary material, approximately 122 KB.


  1. 1.
    Custer B, Sullivan SD, Hazlet TK, et al. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004; 38: S158–68CrossRefGoogle Scholar
  2. 2.
    Lai CL, Ratziu V, Yuen MF, et al. Viral hepatitis B. Lancet 2003; 362: 2089–94PubMedCrossRefGoogle Scholar
  3. 3.
    Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006; 13: 787–98PubMedCrossRefGoogle Scholar
  4. 4.
    Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936–62PubMedCrossRefGoogle Scholar
  5. 5.
    Lee TA, Veenstra DL, Iloeje UH, et al. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004; 38: S144–7CrossRefGoogle Scholar
  6. 6.
    Ganem D, Prince AM. Hepatitis B virus infection: natural history and clinical consequences. N Engl J Med 2004; 350: 1118–29PubMedCrossRefGoogle Scholar
  7. 7.
    Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005; 352: 2743–6PubMedCrossRefGoogle Scholar
  8. 8.
    Lok A, McMahon B. AASLD practice guidelines: chronic hepatitis B. Hepatology 2007; 45: 507–39PubMedCrossRefGoogle Scholar
  9. 9.
    Veenstra DL, Sullivan SD, Clarke L, et al. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Pharmacoeconomics 2007; 25: 963–77PubMedCrossRefGoogle Scholar
  10. 10.
    Lipscomb J, Weinstein MC, Torrance GW. Time preference. In: Gold MR, Siegel JE, Russell LB, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996: 214–46Google Scholar
  11. 11.
    Sennfalt K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scand J Gastroenterol 2001; 36: 870–6PubMedCrossRefGoogle Scholar
  12. 12.
    Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005; 21: 531–7PubMedCrossRefGoogle Scholar
  13. 13.
    Lampertico P, Vigano M, Manenti E, et al. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414–9PubMedCrossRefGoogle Scholar
  14. 14.
    Rapti I, Dimou E, Mitsoula P, et al. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307–13PubMedCrossRefGoogle Scholar
  15. 15.
    Shepherd J, Jones J, Takeda A, et al. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006; 10: iii-iv, xi-xiv, 1–183PubMedGoogle Scholar
  16. 16.
    Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. Jama 2006; 295: 65–73PubMedCrossRefGoogle Scholar
  17. 17.
    Iloeje UH, Yang HI, Su J, et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678–86PubMedCrossRefGoogle Scholar
  18. 18.
    Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743–51PubMedCrossRefGoogle Scholar
  19. 19.
    Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006; 354: 1001–10PubMedCrossRefGoogle Scholar
  20. 20.
    Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348: 808–16PubMedCrossRefGoogle Scholar
  21. 21.
    Lai CL, Gane E, Liaw YF, et al. Telbivudinalpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75Google Scholar
  22. 22.
    Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682–95PubMedCrossRefGoogle Scholar
  23. 23.
    Marcellin P, Chang TT, Lim SG, et al. Long term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic and biochemical response over time. American Association for the Study of Liver Diseases; 2004 29 Oct–2 Nov; Boston (MA)Google Scholar
  24. 24.
    Qi X, Snow A, Thibault V, et al. Long-term incidence of adefovir dipivoxil resistance in chronic hepatitis B patients after 144 weeks of therapy. European Association for the Study of the Liver (EASL); 2004 Apr 14–18; BerlinGoogle Scholar
  25. 25.
    Tenney DJ, Pokorowski KA, Rose RE, et al. Entecavir at five years shows long-term maintenance of high genetic barrier to hepatitis B virus resistance. 18th Conference of the Asia-Pacific Association for the Study of the Liver (APASL); 2008 Mar 23–26; SeoulGoogle Scholar
  26. 26.
    Han SH, Lai CL, Gane E, et al. Telbivudine GLOBE trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B. In Digestive Disease Week; 2007 May 24–27; Washington DCGoogle Scholar
  27. 27.
    Perrillo R, Hann HW, Mutimer D, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90PubMedCrossRefGoogle Scholar
  28. 28.
    Salomon JA, Weinstein MC, Hammitt JK, et al. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003; 290: 228–37PubMedCrossRefGoogle Scholar
  29. 29.
    Marcellin P, Chang TT, Lim SG, et al. Long-term efficacy and safety of adefovir dipivoxil (ADV) in HBeAg+ chronic hepatitis B patients: increasing serologic, virologic, and biochemical response over time [abstract no. 1135]. Hepatology 2004; 40: 655AGoogle Scholar
  30. 30.
    Heathcote E, Jeffers L, Perrillo R, et al. Sustained anti-viral response and lack of viral resistance with long term adefovir dipivoxil (ADV) therapy in chronic HBV infection [abstract no. 590]. 37th Annual Meeting of the European Association for the Study of the Liver; 2002 Apr 18–22; MadridGoogle Scholar
  31. 31.
    Hepsera® (adefovir dipivoxil tables) [package insert]. Foster City (CA): Gilead Sciences, Inc., 2006Google Scholar
  32. 32.
    Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971–5PubMedCrossRefGoogle Scholar
  33. 33.
    Veenstra DL, Sullivan SD, Dusheiko GM, et al. Cost-effectiveness of peginterferon alpha-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom. Eur J Gastroenterol Hepatol 2007; 19: 631–8PubMedCrossRefGoogle Scholar
  34. 34.
    AnalySource. Wholesale acquisition cost. New York: AnalySource Inc., 2008Google Scholar
  35. 35.
    Crowley S, Tognarini D, Desmond P, et al. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002; 17: 153–64PubMedCrossRefGoogle Scholar
  36. 36.
    Kanwal F, Gralnek IM, Martin P, et al. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005; 142: 821–31PubMedGoogle Scholar
  37. 37.
    Levy AR, Gagnon YM, Hargreaves SJ, et al. Valuing health states using utility weights to capture the impact of disease progression in chronic hepatitis B. World Congress of Gastroenterology; 2005 Sep 9–14; Montreal (QC)Google Scholar
  38. 38.
    Wong JB, Koff RS, Tine F, et al. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995; 122: 664–75PubMedGoogle Scholar
  39. 39.
    Briggs A. Probabilistic analysis of cost-effectiveness models: statistical representation of parameter uncertainty. Value Health 2005; 8: 1–2PubMedCrossRefGoogle Scholar
  40. 40.
    Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001; 10: 779–87PubMedCrossRefGoogle Scholar
  41. 41.
    Fenwick E, Marshall DA, Levy Ar, et al. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006; 6: 52[online]. Available from URL: [Accessed 2008 Sep 12]PubMedCrossRefGoogle Scholar
  42. 42.
    Groot Koerkamp B, Hunink MG, Stijnen T, et al. Limitations of acceptability curves for presenting uncertainty in cost-effectiveness analysis. Med Decis Making 2007; 27: 101–11PubMedCrossRefGoogle Scholar
  43. 43.
    Wilber R, Brett-Smith H, Zhu J, et al. Entecvir (ETV) vs adefovir (ADV): HBV DNA reduction in chronically infected HBeAg (+) nucleoside-naive adults in a 12-week viral kinetics study. NIH Management of Hepatitis B Conference; 2006 Apr 6; Bethesda (MD)Google Scholar
  44. 44.
    Yuan Y, Iloeje UH, Hay J, et al. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm 2008; 14: 21–33PubMedGoogle Scholar
  45. 45.
    Smith VE, Bruno CJ. The search for cost-effective treatment of chronic hepatitis B. J Manag Care Pharm 2008; 14: 61–4PubMedGoogle Scholar
  46. 46.
    Kanwal F, Farid M, Martin P, et al. Treatment alternatives for hepatitis B cirrhosis: a cost-effectiveness analysis. Am J Gastroenterol 2006; 101: 2076–89PubMedCrossRefGoogle Scholar
  47. 47.
    Chan HL, Heathcote EJ, Marcellin P, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med 2007; 147: 745–54PubMedGoogle Scholar
  48. 48.
    Tan J, Degertekin B, Wong SN, et al. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48: 391–8PubMedCrossRefGoogle Scholar
  49. 49.
    Reijnders JG, Janssen HL. Potency of tenofovir in chronic hepatitis B: mono or combination therapy? J Hepatol 2008; 48: 383–6PubMedCrossRefGoogle Scholar
  50. 50.
    Lai CL, Chien RN, Leung NW, et al. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998 Jul 9; 339 (2): 61–8PubMedCrossRefGoogle Scholar
  51. 51.
    Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996 May 30; 334 (22): 1422–7PubMedCrossRefGoogle Scholar
  52. 52.
    Crowley SJ, Tognarini D, Desmond PV, et al. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 2000; 17: 409–27PubMedCrossRefGoogle Scholar
  53. 53.
    Gish RG, Lok AS, Chang TT, et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133: 1437–44PubMedCrossRefGoogle Scholar
  54. 54.
    Degertekin B, Lok AS. When to start and stop hepatitis B treatment: can one set of criteria apply to all patients regardless of age at infection? Ann Intern Med 2007; 147: 62–4PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Pharmaceutical Outcomes Research and Policy Program, Department of PharmacyUniversity of WashingtonSeattleUSA

Personalised recommendations